Enhanced Drug Distribution Security Guidance for Pharmacists

December 15, 2021 | 1-2 PM CST

This webinar will provide an overview of the enhanced drug distribution security requirements that will go into effect in 2023. Presenters from Food and Drug Administration (FDA) will discuss updates about important guidance recently published regarding supply chain security requirements and changes for pharmacies in 2023 and beyond. Specifically, the presenters will:

  1. Review four industry guidance documents that describe proposed and final agency recommendations related to the requirements under the Drug Supply Chain Security Act (DSCSA).
  2. Discuss enhanced drug distribution security requirements that will go into effect in November 2023.
  3. Provide examples to help pharmacists understand enhanced product tracing and verification requirements.

CPE Credit

The complimentary webinar is eligible for Accreditation Council for Pharmacy Education (ACPE)-accredited continuing pharmacy education (CPE) credit. More details regarding the presentations, CPE activity credits, and browser requirements can be found in the CPE Activity Information Guide.

Presenters

Headshot of Connie Jung
Connie Jung, PhD, RPh Senior Advisor for Policy, FDA CDER, OC, ODSIR

Dr Jung is currently senior advisor for Policy in the Office of Drug Security, Integrity, and Response (ODSIR) in the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER), Office of Compliance (OC). Her work focuses on the development of policy and regulatory strategies to improve the security and integrity of the United States drug supply to protect patients from counterfeit or stolen product. She received her bachelor of science degree in pharmacy from The Ohio State University and her doctorate degree in pharmaceutical sciences from the University of Cincinnati. Dr Jung joined FDA in 1999 as a toxicology researcher in the Center for Food Safety and Applied Nutrition, and later served as a Regulatory Reviewer of bioequivalence studies in the Office of Generic Drug before working on supply chain issues.


Headshot of Abha Kundi
Abha Kundi, MPH, JD Regulatory Counsel, FDA CDER, OC, ODSIR

Abha Kundi is a regulatory counsel in the ODSIR in FDA’s CDER, OC. During her 10 years with FDA, Abha’s work has primarily focused on the development of policy and regulatory strategies to improve the security and integrity of the US drug supply. Abha received both her law degree and master’s degree in public health from Boston University.